JPRN-UMIN000004173已完成未知
Global Clinical Study on Ethnic Differences in Drug Metabolism Based on the Joint Statement by the Japanese, Chinese and Korean Ministers of Health: Clinical Pharmacokinetic Study of Meloxicam in Healthy Adult Male Subjects - Comparative Pharmacokinetic Study of Meloxicam among Japan, Korea, China, and USA.
Research Group of Global Clinical Study on Ethnic Differences in Drug Metabolism Based on the Announcement by the Japanese, Chinese and Korean Ministers of Health, Labor and Welfare0 个研究点目标入组 120 人开始时间: 2010年10月14日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 35years-old（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1)Organopathy involving the heart, lung, liver and/or kidney etc. 2)Persons with diseases of heart, lung, kidney, blood, central nervous system and metabolic system, peptic ulcer, inflammatory enteropathy, hypertension, asthma and diseases of skeletal muscles, etc. and those with a history of any of the above diseases. 3)Persons with hypersensitivity or allergy to drugs, foods, etc. 5)Persons who are smoking or those have stopped smoking in 6 months. (the cotinine test is conducted if necessary.) 6)Persons who are drug-dependent or those suspected to be drug-dependent. (drug screening is conducted if necessary.) 7)Habitual alcohol drinkers (persons with 50 g or more of alcohol intake per day). 8)Total bilirubin or direct bilirubin, AST, ALT and ALP is 1.5 times higher, or other liver and renal function tests items are 1.25 times higher than the upper limits of normal at the sites. 9)Persons who underwent 200 mL or more of blood collection within one month, blood component donation (plasma or platelet) within two weeks or those who underwent more than 400 mL blood collection within 3 months before administration of the study drug. 10)Persons who participated in a phase I study on drugs containing new active ingredient within 4 months, or those who participated in other studies and received administration within 3 months, before administration of the study drug (For patch test, those who received within one month before administration of the study drug). And persons who participated in any of the above studies and received administration outside the defined period shall also be excluded, if determined to be inappropriate for participation in the study, considering the characteristics of the previous investigational product. 11)Other persons determined by the principal investigator to be inappropriate for the study.
研究者
相似试验
已完成
不适用
Global Clinical Study on Ethnic Differences in Drug Metabolism Based on the Joint Statement by the Japanese, Chinese and Korean Ministers of Health: Clinical Pharmacokinetic Study of Moxifloxacin in Healthy Adult Male Subjects.Healthy adult male subjectsJPRN-UMIN000002968Research Group of Global Clinical Study on Ethnic Differences in Drug Metabolism Based on the Announcement by the Japanese, Chinese and Korean Ministers of Health, Labor and Welfare80
已完成
不适用
Global Clinical Study on Ethnic Differences in Drug Metabolism Based on the Joint Statement by the Japanese, Chinese and Korean Ministers of Health: Clinical Pharmacokinetic Study of Simvastatin in Healthy Adult Male Subjects.Healthy adult male subjectsJPRN-UMIN000003644Research Group of Global Clinical Study on Ethnic Differences in Drug Metabolism Based on the Announcement by the Japanese, Chinese and Korean Ministers of Health, Labor and Welfare160
进行中（未招募）
Unknown
Effectiveness of a food supplement on hair lossAcute telogen effluvium from less than 6 months (presenting =15% of telogen parameter at inclusion), with a hair length of at least 5 cm, complaining of brittle and thin hairSkin and Connective Tissue DiseasesISRCTN12522754ROELMI HPC Srl60
尚未招募
2 期
Daruharidra madhu kwath aschyotana and triphala kwath aschyotana in vataj abhishadhaCTRI/2022/12/048002Dr Snehal Sampatrao Pakhare
已完成
不适用
*Interculturalisation: Diagnostic Evaluation with Ethnic minority patients with Low back disabilities* (IDEAL)NL-OMON30507JBI - Instituut voor Reumatologie en Revalidatie35